CDH2 and hepatocellular carcinoma: (2015), sorafenib inhibits the up-regulation of p-Akt and p-ERK1/2 in HCC cells after insufficient RFA, and further down-regulates the expression of N-cadherin, vimentin, and snail, resulting in enhanced migration and invasion of HCC cells after insufficient RFA.